Results 91 to 100 of about 279,790 (190)

New development in CAR-T cell therapy

Journal of Hematology & Oncology, 2017
Chimeric antigen receptor (CAR)-engineered T cells (CAR-T cells) have yielded unprecedented efficacy in B cell malignancies, most remarkably in anti-CD19 CAR-T cells for B cell acute lymphoblastic leukemia (B-ALL) with up to a 90% complete remission rate. However, tumor antigen escape has emerged as a main challenge for the long-term disease control of
Zhenguang Wang, Zhiqiang Wu, Yang Liu, Weidong Han   +3 more
openaire   +3 more sources

Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. [PDF]

, 2020
Head and neck squamous cell carcinomas (HNSCCs) are malignancies that originate in the mucosal lining of the upper aerodigestive tract. Despite advances in therapeutic interventions, survival rates among HNSCC patients have remained static for years ...
Abouyared, Marianne, Anderson, Johnathon D, Archard, Joehleen A, Belafsky, Peter C, Beliveau, Angela, Bewley, Arnaud F, Birkeland, Andrew, Clayton, Shannon M, Farwell, D Gregory, Rao, Shyam, Wagner, Joseph   +10 more
core   +1 more source

CRISPR Meets CAR T-cell Therapy [PDF]

Cancer Discovery, 2017
Abstract Using CRISPR/Cas9 technology, researchers have devised a method to deliver a CAR gene to a specific locus, TRAC, in T cells. This targeted approach yielded therapeutic cells that were more potent even at low doses; in a mouse model of acute lymphoblastic leukemia, they outperformed CAR T cells created with a randomly integrating
openaire   +2 more sources

CD4+ T Cell Count Recovery in HIV Type 1-Infected Patients Is Independent of Class of Antiretroviral Therapy [PDF]

, 2017
Background. In recent years, treatment options for human immunodeficiency virus type 1 (HIV-1) infection have changed from nonboosted protease inhibitors (PIs) to nonnucleoside reverse-transcriptase inhibitors (NNRTIs) and boosted PI-based antiretroviral
Battegay, Manuel, Bernasconi, Enos, Cavassini, Matthias, Furrer, Hansjakob, Hirschel, Bernard, Kaufmann, Gilbert R., Khanna, Nina, Opravil, Milos, Vernazza, Pietro, Weber, Rainer   +9 more
core  

Production of Living Nanoparticles for Blood Cancer Therapy [PDF]

, 2018
Current cancer therapies leave much to be desired because they are very harmful to the patient and cause a significant decrease in quality of life. Chimeric Antigen Receptors (CAR) are a promising novel approach for treating specific types of leukemia ...
Mitchell, Peter, Pierotti, Michael, Piro, Matthew   +2 more
core   +1 more source

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Cancer Cell International
The application of chimeric antigen receptor (CAR) T cells in the management of hematological malignancies has emerged as a noteworthy therapeutic breakthrough.
Tong Chen, Mingzhao Wang, Yanchao Chen, Yutao Liu   +3 more
doaj   +1 more source

Targeting the gut microbiota to enhance the antitumor efficacy and attenuate the toxicity of CAR-T cell therapy: a new hope?

Frontiers in Immunology
Chimeric antigen receptor (CAR) -T cell therapy has achieved tremendous efficacy in the treatment of hematologic malignancies and represents a promising treatment regimen for cancer. Despite the striking response in patients with hematologic malignancies,
Peng-Fei Zhang, Dan Xie, Dan Xie
doaj   +1 more source

Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology

Frontiers in Immunology
CAR-T cell therapy, a novel immunotherapy, has made significant breakthroughs in clinical practice, particularly in treating B-cell-associated leukemia and lymphoma.
Ruiyu Tao, Xiaopeng Han, Xue Bai, Jianping Yu, Youwei Ma, Weikai Chen, Dawei Zhang, Zhengkai Li   +7 more
doaj   +1 more source

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver. [PDF]

, 2007
We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the liver. Thirty-five patients enrolled in this multi-institutional phase I/II trial received up to eight arterial infusions ...
Au, T, Kirn, D, Korn, WM, Reid, TR, Sze, D, Thorne, S   +5 more
core  

CAR-T CELL THERAPY IN LYMPHOMAS: EXPANSİON OF INDICATIONS AND NEW APPROACHES

Hematology, Transfusion and Cell Therapy
CAR-T (chimeric antigen receptor T-cell) therapy represents a revolutionary advance in treating hematologic cancers, offering promising outcomes for lymphoma patients, especially those with relapsed or refractory disease.
Ayfer Gedük
doaj   +1 more source